Dr. Bei Zhang 张蓓
Chief Physician
Department of Comprehensive Oncology, Sun Yat-sen University Cancer Center, Guangzhou
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Integrated traditional Chinese and Western medicine for cancer care, including nasopharyngeal, breast, lung, esophageal, liver, colorectal, gastric, and gynecologic tumors.
Dr. Zhang is Director of the Department of Integrated Traditional Chinese and Western Medicine at Sun Yat-sen University Cancer Center. Trained at Guangzhou University of Chinese Medicine, Dr. Zhang has practiced since 1985, specializing in combining Chinese medicine with conventional cancer treatments to manage side effects and improve quality of life.
Professional roles
- Standing Committee Member, Oncology Professional Committee, China Association of Chinese Medicine
- Vice Chair, Oncology Professional Committee, Guangdong Association of Integrative Medicine
- Vice Chair, Integrated Traditional Chinese and Western Medicine Oncology Professional Committee, Guangzhou Anti-Cancer Association
- Associate Editor, Journal of Chinese Medicinal Materials
Name order: in Chinese the family name comes first (Zhang Bei). Papers usually list the name as Bei Zhang or Zhang B.
Selected publications
87 papers on PubMed matched by name and affiliation; 11 as first or senior author since 2016. Most recent first- or senior-author papers:
- Int J Biol Sci, 2026 (senior author): Co-targeting MRPS7-23 synergistically enhances cisplatin efficacy to suppress nasopharyngeal carcinoma growth and metastasis. PubMed 41522354
- Front Pharmacol, 2025 (senior author): Uncovering the molecular mechanisms of Qingdu Zengye Decoction in the treatment of nasopharyngeal carcinoma: an integrative investigation. PubMed 40746726
- Front Immunol, 2024 (senior author): Nasopharyngeal carcinoma-associated inflammatory cytokines: ongoing biomarkers. PubMed 39483474
- Drug Des Devel Ther, 2024 (senior author): Unveiling the Mechanism of the ChaiShao Shugan Formula Against Triple-Negative Breast Cancer. PubMed 38618280
- PLoS One, 2024 (senior author): Association between multiple sclerosis and cancer risk: A two-sample Mendelian randomization study. PubMed 38502664
- Cancer Immunol Immunother, 2022 (senior author): Efficacy and safety of PD-L1 inhibitors versus PD-1 inhibitors in first-line treatment with chemotherapy for extensive-stage small-cell lung cancer. PubMed 34297160
- Leuk Res, 2020 (senior author): Cutaneous extranodal natural killer (NK) / T - cell lymphoma: A comprehensive clinical features and outcomes analysis of 71 cases. PubMed 31841860
- Transl Cancer Res, 2019 (senior author): Inflammation-based markers can predict the prognosis of geriatric patients with metastatic colorectal cancer receiving first-line chemotherapy. PubMed 35116856
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital. This name is shared by other researchers, so we checked that the papers match this doctor's specialty; this check is automatic.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion